VectivBio, a clinical-stage biotechnology company developing transformational medicines for patients with serious rare diseases, announced that it has closed a USD 110 m crossover financing from new investors Surveyor Capital (a Citadel company), Cormorant Capital and Eventide Asset Management, with participation from existing investors Versant Ventures, OrbiMed, Novo Holdings, BPI France, Tekla Healthcare Investors, Inserm Transfert Initiative and Cowen Healthcare Investments.
Proceeds from the financing will be used to support the further clinical development of VectivBio’s lead investigational product, apraglutide, to treat short bowel syndrome (SBS), early commercialization activities and further development of the pipeline through business development initiatives.
Homburger advises VectivBio on USD 110 m crossover financing.The team was led by partner Andreas Müller (pictured left) and included lead associate Margrit Marti, associates Angela Oppliger and Mirko Stiefel and transaction and corporate support specialist Carolina Rodriguez (all Corporate/M&A), partner Luca Dal Molin and associate Kirsten Schmidt (both IP/IT) as well as partner Stefan Oesterhelt and associates Joël Gyger and Raphaël Fellay (all Tax).
Walder Wyss advised BPI France, Cowen Healthcare Investments, Novo Ventures, OrbiMed and Versant Ventures as lead investors on the transaction. The team included Alexander Gutmans (Partner, Corporate/M&A and Venture Capital – picture right) and Karina Tschon (Associate, Corporate/M&A and Venture Capital).
Lenz & Staehelin advised Surveyor Capital on the Swiss aspects of this transaction. The team comprised partner Andreas Rötheli and senior associate Federico Trabaldo Togna (both Corporate and M&A). Choate, Hall & Stewart acted as international counsel to Surveyor Capital.